Amgen’s KRAS Inhibitor Shows Durability; Pivotal Data Possible This Year
Ongoing Phase II Study Could Support Accelerated Approval
Executive Summary
Newly published data and results presented at ESMO for Amgen’s sotorasib (AMG 510) show relatively long-lasting responses and progression-free survival in lung cancer.